2023 Fiscal Year Final Research Report

a

Research Project

PDF

Project/Area Number	20H03645
Research Category	Grant-in-Aid for Scientific Research (B)
Allocation Type	Single-year Grants
Section	一般
Review Section	Basic Section 52050:Embryonic medicine and pediatrics-related
Research Institution	Kagoshima University
Principal Investigator	Kosai Ken-ichiro 鹿児島大学, 医歯学域医学系, 教授 (90258418)
Co-Investigator(Kenkyū-buntansha)	永野聡鹿児島大学, 医歯学域医学系, 教授 (50373139) 三井薫鹿児島大学, 医歯学域医学系, 准教授 (40324975) 伊地知暢広鹿児島大学, 医歯学域医学系, 助教 (80380624) 入江理恵鹿児島大学, 医歯学総合研究科, 技術職員 (90381178)
Project Period (FY)	2020-04-01 – 2023-03-31
Keywords	癌 / ウイルス / 遺伝子 / 免疫学
Outline of Final Research Achievements	We developed the m-CRA platform technology for next-generation oncolytic viruses (OVs). Our first drug, Surv. m-CRA-1, demonstrated high safety and therapeutic efficacy in a first-in-human, investigator-initiated clinical trial for patients with malignant bone and soft tissue tumors. Next, we developed Surv.m-CRA-2 armed with GM-CSF gene for the treatment of invasive and metastatic cancers, and preclinical studies are underway. In this study, we have developed innovative immune gene/virus therapies that can more efficiently induce systemic anti-tumor immunity by local administration and suppress systemic metastases and invasive tumors. Novel OVs expressing immune checkpoints and antibody genes for novel cancer-related surface molecules, and novel OVs expressing soluble membrane protein genes functioned properly. These novel OVs has demonstrated a potent therapeutic effect on primary tumors and induction of systemic anti-tumor immunity to suppress metastatic tumors.
Free Research Field	遺伝子治療学
Academic Significance and Societal Importance of the Research Achievements	独自開発のm-CRAプラットファオーム技術で、新規の治療遺伝子・発現システムを搭載する次世代OVを開発することは、科学的な独創性と意義が大きい。さらにこれらの新規OVが革新的治療作用を示し、本研究の科学的成果が最終的に画期的な癌治療薬の実現に繋がれば、その科学的、社会的意義は限りなく大きい。さらに本邦で遅れている本遺伝子治療の分野で、本研究成果が本邦発の画期的創薬開発に繋がれば、この分野全体の発展に貢献するという意義もある。長期的には「本邦発の革新医薬の創出」により国民福祉や経済の向上という大きな波及効果も期待できる意義を持つ。